Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
Plus Therapeutics (Nasdaq: PSTV), a clinical-stage pharmaceutical firm, announced that Dr. Melissa Moore, VP of Clinical Research and Development, will present at the Gordon Research Conference on July 8, 2024, in Newry, Maine. The presentation, scheduled for 11:30 a.m. EDT, will cover data from the ReSPECT-GBM and ReSPECT-LM studies. These trials evaluate the company's lead radiotherapeutic, rhenium (186Re) obisbemeda, for treating recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). Plus Therapeutics focuses on developing targeted radiotherapeutics for CNS cancers, utilizing advanced platform technologies and strategic partnerships for potential product commercialization.
- None.
- None.
AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that Melissa Moore, Ph.D., Vice President, Clinical Research and Development, will give a presentation at 11:30 a.m. EDT at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer on July 8, 2024 in Newry, Maine.
The presentation will report data from the ReSPECT-GBM and ReSPECT-LM clinical studies evaluating the Company’s lead radiotherapeutic, rhenium (186Re) obisbemeda, for the treatment of recurrent glioblastoma (GBM) and leptomeningeal metastases (LM).
Details of presentations:
| Title | Targeted Radiolabeled Nanoliposomes for Rare CNS Cancers: An Update on the ReSPECT Phase 1/2 Trials |
| Date | July 8, 2024, 11:30 a.m. EDT |
| Session | Clinical Trial Updates in Radionuclide Theranostics |
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). The Company has built a supply chain through strategic partnerships that enable the development, manufacturing, and future potential commercialization of its products. Plus Therapeutics is led by an experienced and dedicated leadership team and has operations in key cancer clinical development hubs including Austin and San Antonio, Texas. For more information, visit https://plustherapeutics.com/.
Investor Contact
Charles Y. Huang, MBA
Director of Capital Markets and Investor Relations
Office: (202)-209-5751 | Direct (301)-728-7222
chuang@plustherapeutics.com
FAQ
What is Plus Therapeutics' stock symbol?
When and where is Plus Therapeutics presenting their clinical trial data?
What clinical studies will Plus Therapeutics discuss at the conference?
What is the focus of Plus Therapeutics' presentation at the Gordon Research Conference?
What is rhenium (186Re) obisbemeda?
Who will present on behalf of Plus Therapeutics at the Gordon Research Conference?
What type of cancers is Plus Therapeutics focusing on?
Where can I find more information about Plus Therapeutics?
